Design Therapeutics (DSGN) Share-based Compensation (2020 - 2026)

Design Therapeutics has disclosed Share-based Compensation across 7 years of filings, most recently posting $3.9 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $3.9 million, up 10.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.9 million (up 11.22% YoY), and the FY2025 annual result was $14.5 million, up 11.3% from the prior year.
• Share-based Compensation came in at $3.9 million for Q1 2026 at Design Therapeutics, up from $3.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.0 million in Q2 2025 to a low of $2.4 million in Q1 2022.
• The 5-year median for Share-based Compensation is $3.3 million (2024), against an average of $3.3 million.
• Across the five-year window, Share-based Compensation jumped 264.76% in 2022 and declined 11.44% in 2023, its largest moves.
• Design Therapeutics' Share-based Compensation stood at $3.1 million in 2022, then decreased by 11.44% to $2.7 million in 2023, then gained by 27.42% to $3.5 million in 2024, then declined by 1.04% to $3.4 million in 2025, then advanced by 14.24% to $3.9 million in 2026.
• The last three Share-based Compensation figures came in at $3.9 million (Q1 2026), $3.4 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.